Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jun;39(6):1369–1371. doi: 10.1128/aac.39.6.1369

Protection of mice from Mycobacterium avium infection by recombinant interleukin-12.

K Kobayashi 1, T Kasama 1, J Yamazaki 1, M Hosaka 1, T Katsura 1, T Mochizuki 1, K Soejima 1, R M Nakamura 1
PMCID: PMC162744  PMID: 7574533

Abstract

Treatment with interleukin-12 (IL-12) significantly reduced the number of viable bacteria in mice infected with Mycobacterium avium. IL-12 itself, however, could not inhibit directly mycobacterial growth in vitro. IL-12 exerts antimycobacterial activity in vivo with a low level of toxicity, possibly by enhancing the host defense against the infection.

Full Text

The Full Text of this article is available as a PDF (203.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bermudez L. E., Martinelli J., Petrofsky M., Kolonoski P., Young L. S. Recombinant granulocyte-macrophage colony-stimulating factor enhances the effects of antibiotics against Mycobacterium avium complex infection in the beige mouse model. J Infect Dis. 1994 Mar;169(3):575–580. doi: 10.1093/infdis/169.3.575. [DOI] [PubMed] [Google Scholar]
  2. Bermudez L. E., Stevens P., Kolonoski P., Wu M., Young L. S. Treatment of experimental disseminated Mycobacterium avium complex infection in mice with recombinant IL-2 and tumor necrosis factor. J Immunol. 1989 Nov 1;143(9):2996–3000. [PubMed] [Google Scholar]
  3. Brunda M. J. Interleukin-12. J Leukoc Biol. 1994 Feb;55(2):280–288. doi: 10.1002/jlb.55.2.280. [DOI] [PubMed] [Google Scholar]
  4. Collins F. M., Watson S. R. Immune responses to atypical mycobacterial lung infections. Rev Infect Dis. 1981 Sep-Oct;3(5):981–989. doi: 10.1093/clinids/3.5.981. [DOI] [PubMed] [Google Scholar]
  5. Dannenberg A. M., Jr Delayed-type hypersensitivity and cell-mediated immunity in the pathogenesis of tuberculosis. Immunol Today. 1991 Jul;12(7):228–233. doi: 10.1016/0167-5699(91)90035-R. [DOI] [PubMed] [Google Scholar]
  6. Denis M. Interferon-gamma-treated murine macrophages inhibit growth of tubercle bacilli via the generation of reactive nitrogen intermediates. Cell Immunol. 1991 Jan;132(1):150–157. doi: 10.1016/0008-8749(91)90014-3. [DOI] [PubMed] [Google Scholar]
  7. Denis M. Modulation of Mycobacterium avium growth in vivo by cytokines: involvement of tumour necrosis factor in resistance to atypical mycobacteria. Clin Exp Immunol. 1991 Mar;83(3):466–471. doi: 10.1111/j.1365-2249.1991.tb05662.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am Rev Respir Dis. 1990 Oct;142(4):940–953. doi: 10.1164/ajrccm/142.4.940. [DOI] [PubMed] [Google Scholar]
  9. Doi T., Ando M., Akaike T., Suga M., Sato K., Maeda H. Resistance to nitric oxide in Mycobacterium avium complex and its implication in pathogenesis. Infect Immun. 1993 May;61(5):1980–1989. doi: 10.1128/iai.61.5.1980-1989.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Edwards C. K., 3rd, Hedegaard H. B., Zlotnik A., Gangadharam P. R., Johnston R. B., Jr, Pabst M. J. Chronic infection due to Mycobacterium intracellulare in mice: association with macrophage release of prostaglandin E2 and reversal by injection of indomethacin, muramyl dipeptide, or interferon-gamma. J Immunol. 1986 Mar 1;136(5):1820–1827. [PubMed] [Google Scholar]
  11. Edwards D., Kirkpatrick C. H. The immunology of mycobacterial diseases. Am Rev Respir Dis. 1986 Nov;134(5):1062–1071. doi: 10.1164/arrd.1986.134.5.1062. [DOI] [PubMed] [Google Scholar]
  12. Ehlers S., Mielke M. E., Hahn H. Progress in TB research: Robert Koch's dilemma revisited. Immunol Today. 1994 Jan;15(1):1–4. doi: 10.1016/0167-5699(94)90015-9. [DOI] [PubMed] [Google Scholar]
  13. Gangadharam P. R., Edwards C. K., 3rd, Murthy P. S., Pratt P. F. An acute infection model for Mycobacterium intracellulare disease using beige mice: preliminary results. Am Rev Respir Dis. 1983 May;127(5):648–649. doi: 10.1164/arrd.1983.127.5.648. [DOI] [PubMed] [Google Scholar]
  14. Gazzinelli R. T., Hieny S., Wynn T. A., Wolf S., Sher A. Interleukin 12 is required for the T-lymphocyte-independent induction of interferon gamma by an intracellular parasite and induces resistance in T-cell-deficient hosts. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):6115–6119. doi: 10.1073/pnas.90.13.6115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Goto Y., Nakamura R. M., Takahashi H., Tokunaga T. Genetic control of resistance to Mycobacterium intracellulare infection in mice. Infect Immun. 1984 Oct;46(1):135–140. doi: 10.1128/iai.46.1.135-140.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Heinzel F. P., Schoenhaut D. S., Rerko R. M., Rosser L. E., Gately M. K. Recombinant interleukin 12 cures mice infected with Leishmania major. J Exp Med. 1993 May 1;177(5):1505–1509. doi: 10.1084/jem.177.5.1505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Kasahara K., Kobayashi K., Shikama Y., Yoneya I., Kaga S., Hashimoto M., Odagiri T., Soejima K., Ide H., Takahashi T. The role of monokines in granuloma formation in mice: the ability of interleukin 1 and tumor necrosis factor-alpha to induce lung granulomas. Clin Immunol Immunopathol. 1989 Jun;51(3):419–425. doi: 10.1016/0090-1229(89)90040-8. [DOI] [PubMed] [Google Scholar]
  18. Kaufmann S. H. Immunity to intracellular bacteria. Annu Rev Immunol. 1993;11:129–163. doi: 10.1146/annurev.iy.11.040193.001021. [DOI] [PubMed] [Google Scholar]
  19. Scott P. IL-12: initiation cytokine for cell-mediated immunity. Science. 1993 Apr 23;260(5107):496–497. doi: 10.1126/science.8097337. [DOI] [PubMed] [Google Scholar]
  20. Sypek J. P., Chung C. L., Mayor S. E., Subramanyam J. M., Goldman S. J., Sieburth D. S., Wolf S. F., Schaub R. G. Resolution of cutaneous leishmaniasis: interleukin 12 initiates a protective T helper type 1 immune response. J Exp Med. 1993 Jun 1;177(6):1797–1802. doi: 10.1084/jem.177.6.1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Trinchieri G., Scott P. The role of interleukin 12 in the immune response, disease and therapy. Immunol Today. 1994 Oct;15(10):460–463. doi: 10.1016/0167-5699(94)90189-9. [DOI] [PubMed] [Google Scholar]
  22. Zhang M., Gately M. K., Wang E., Gong J., Wolf S. F., Lu S., Modlin R. L., Barnes P. F. Interleukin 12 at the site of disease in tuberculosis. J Clin Invest. 1994 Apr;93(4):1733–1739. doi: 10.1172/JCI117157. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES